cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Theravance Biopharma Inc
9 own
7 watching
Current Price
$9.17
$-0.05
(-0.54%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
514.87M
52-Week High
52-Week High
11.98000
52-Week Low
52-Week Low
8.21000
Average Volume
Average Volume
0.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization514.87M
icon52-Week High11.98000
icon52-Week Low8.21000
iconAverage Volume0.3M
iconDividend Yield--
iconP/E Ratio--
What does the Theravance Biopharma Inc do?
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The company's product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Read More
How much money does Theravance Biopharma Inc make?
News & Events about Theravance Biopharma Inc.
Ticker Report
1 year ago
Theravance Biopharma, Inc. (NASDAQ:TBPH Get Rating) SVP Richard A. Graham sold 2,323 shares of the businesss stock in a transaction that occurred on Friday, April 14th. The stock was sold at an average price of $11.88, for a total transaction of $27,597.24. Following the sale, the ...
Business Wire
1 year ago
Irenic Capital Management, LP (together with its affiliates, Irenic or we), a top shareholder of Theravance Biopharma, Inc. (NASDAQ: TBPH) (Theravance or the Company), today issued the following statement regarding the Companys appointment of Jim Kelly, Managing Director at Weiss Asset Management...
PR Newswire
1 year ago
Theravance Biopharma to Participate in an Upcoming Investor Conference Theravance Biopharma to Participate in an Upcoming Investor Conference PR Newswire DUBLIN, April 10, 2023 DUBLIN, April 10, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the 22nd Annual Needham...
Ticker Report
1 year ago
StockNews.com cut shares of Theravance Biopharma (NASDAQ:TBPH Get Rating) from a buy rating to a hold rating in a research note issued to investors on Tuesday. A number of other research analysts also recently commented on the stock. HC Wainwright increased their target price on shares of ...
PR Newswire
1 year ago
Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer PR Newswire DUBLIN, Nov. 18, 2022 DUBLIN, Nov. 18, 2022 /PRNewswire/ -- Theravance Biopharma, Inc. ('Theravance Biopharma' or the...
Frequently Asked Questions
Frequently Asked Questions
What is Theravance Biopharma Inc share price today?
plus_minus_icon
Can Indians buy Theravance Biopharma Inc shares?
plus_minus_icon
How can I buy Theravance Biopharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Theravance Biopharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Theravance Biopharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Theravance Biopharma Inc?
plus_minus_icon
What is today’s market capitalisation of Theravance Biopharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Theravance Biopharma Inc?
plus_minus_icon
What percentage is Theravance Biopharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Theravance Biopharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.17
$-0.05
(-0.54%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
WAVE LIFE SCIENCES LTD
WAVE LIFE SCIENCES LTD
$5.01
$-0.07 (-1.38 %)
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$35.48
$-0.46 (-1.28 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.52
$-0.01 (-0.40 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$12.56
$-1.05 (-7.71 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
WAVE LIFE SCIENCES LTD
WAVE LIFE SCIENCES LTD
$5.01
$-0.07 (-1.38 %)
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
$35.48
$-0.46 (-1.28 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$2.52
$-0.01 (-0.40 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$12.56
$-1.05 (-7.71 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00